Shares of OvaScience Inc. (NASDAQ:OVAS) traded up 4.2% on Monday . The stock traded as high as $5.29 and last traded at $5.27, with a volume of 210,651 shares traded. The stock had previously closed at $5.06.

Several analysts have recently weighed in on the company. Credit Suisse Group AG reissued an “underperform” rating on shares of OvaScience in a report on Friday, March 25th. Oppenheimer Holdings Inc. restated a “hold” rating on shares of OvaScience in a research report on Monday, April 25th. Finally, Leerink Swann restated a “hold” rating and set a $7.00 target price (up previously from $6.00) on shares of OvaScience in a research report on Sunday, May 8th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $12.37.

The stock’s 50-day moving average is $5.76 and its 200 day moving average is $7.33. The firm’s market capitalization is $135.55 million.

OvaScience (NASDAQ:OVAS) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.08. The business earned $0.15 million during the quarter, compared to analysts’ expectations of $0.14 million. During the same quarter last year, the company earned ($0.65) EPS. The firm’s revenue for the quarter was up 630.0% on a year-over-year basis. Analysts expect that OvaScience Inc. will post ($3.14) earnings per share for the current year.

In other OvaScience news, Director Richard Aldrich acquired 20,000 shares of the company’s stock in a transaction on Wednesday, May 11th. The shares were purchased at an average price of $7.64 per share, for a total transaction of $152,800.00. Following the completion of the purchase, the director now directly owns 604,185 shares of the company’s stock, valued at $4,615,973.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Michelle Dipp acquired 425,000 shares of the company’s stock in a transaction on Wednesday, June 1st. The stock was acquired at an average price of $7.00 per share, for a total transaction of $2,975,000.00. Following the purchase, the chief executive officer now directly owns 971,921 shares of the company’s stock, valued at $6,803,447. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in OvaScience stock. AWM Investment Company Inc. raised its stake in shares of OvaScience Inc. (NASDAQ:OVAS) by 1.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 116,352 shares of the company’s stock after buying an additional 1,352 shares during the period. AWM Investment Company Inc. owned approximately 0.43% of OvaScience worth $1,137,000 as of its most recent SEC filing.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.